R. Kammler

发表

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

P. Neven, S. Loi, M. Piccart, 2022, European journal of cancer.

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

P. Neven, A. Goldhirsch, G. Viale, 2020, Clinical Cancer Research.

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

P. Neven, H. Ditzel, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

P. Neven, R. Gelber, B. Leyland-Jones, 2015, Breast Cancer Research and Treatment.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

P. Neven, R. Gelber, H. Ditzel, 2012, Journal of the National Cancer Institute.

Abstract S1-8: Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial

B. Leyland-Jones, G. Viale, B. Thürlimann, 2010 .

Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.

U. Dafni, R. Stahel, S. Peters, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

U. Dafni, R. Stahel, S. Peters, 2017, The Lancet. Respiratory medicine.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

A. Warth, A. Marchetti, L. Bubendorf, 2019, Lung cancer.

Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study

S. Loi, G. Viale, F. André, 2018 .

Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.

S. Loi, P. Savas, S. Luen, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

K. Nackaerts, U. Dafni, K. Syrigos, 2022, Modern Pathology.

Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry - Clinical associations in NSCLC patients of the ETOP Lungscape cohort

A. Warth, A. Marchetti, H. Moch, 2019 .

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

A. Giobbie-Hurder, S. Loi, G. Viale, 2019, The Lancet. Oncology.

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

U. Dafni, E. Smit, R. Stahel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

R. Gelber, A. Goldhirsch, G. Pruneri, 2016, Breast Cancer Research and Treatment.

Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project.

A. Warth, A. Marchetti, L. Bubendorf, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project

A. Warth, A. Marchetti, L. Bubendorf, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort

C. Dooms, K. Nackaerts, A. Warth, 2019, Modern Pathology.

Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort.

L. Bubendorf, U. Dafni, R. Stahel, 2022, Lung cancer.

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial

S. Loi, P. Savas, G. Viale, 2018, JAMA oncology.

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.

A. Warth, A. Marchetti, L. Bubendorf, 2017, Lung cancer.

Computer‐Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort

A. Warth, A. Marchetti, H. Moch, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial

P. Fasching, C. Denkert, M. Dietel, 2019, Breast Cancer Research and Treatment.

Abstract GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

S. Loi, Yi Zhang, M. Regan, 2023, Cancer Research.

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

B. Bonanni, R. Gelber, A. Goldhirsch, 2016, Breast Cancer Research.

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98

Michael E. Pyle, R. Tamimi, S. Schnitt, 2019, Breast Cancer Research.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

R. Gelber, A. Goldhirsch, G. MacGrogan, 2015, Breast Cancer Research and Treatment.

High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers

R. Gray, S. Loi, B. Leyland-Jones, 2017, JCO precision oncology.

Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

C. Dooms, K. Nackaerts, A. Warth, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98

Michael E. Pyle, R. Tamimi, S. Schnitt, 2019, Breast Cancer Research.

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00

R. Gelber, A. Goldhirsch, G. Viale, 2018, Breast Cancer Research and Treatment.

Abstract PD9-07: Role of immunosuppressive JNK pathway in the tumor microenvironment among Triple Negative Breast Cancer subtypes in IBCSG Trial 22-00

C. Sotiriou, S. Loi, M. Regan, 2023, Cancer Research.

Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.

U. Dafni, E. Smit, A. Dingemans, 2022, Lung cancer.

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

P. Neven, S. Loi, S. Nik-Zainal, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S1-10: Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study

S. Loi, P. Savas, G. Viale, 2017 .